Alnylam Pharmaceuticals announced changes to its Board of Directors, including the departure of two key members and the appointment of a new independent director, Stuart Arbuckle.
Mike Bonney and Carolyn Bertozzi resigned from the board, effective December 2, 2025, after playing crucial roles in Alnylam's growth and success.
Stuart Arbuckle, with extensive biopharmaceutical experience, joined the Board effective January 5, 2026, to support the company's future endeavors.
Leadership Transition
Departure of Mike Bonney and Carolyn Bertozzi, two vital figures in Alnylam's journey, and the appointment of Stuart Arbuckle bring a new phase of leadership to the company.
Stuart Arbuckle's Expertise
Stuart Arbuckle's background in biopharmaceutical commercialization and leadership from notable companies like GSK and Amgen will bring valuable insights to Alnylam.
Strategic Growth
The Board changes aim to support Alnylam's strategic evolution, focusing on advancing a robust pipeline, expanding globally, and sustaining growth in innovative RNAi therapeutics.
- Alnylam acknowledges the significant contributions of departing members while expressing confidence in Stuart Arbuckle's ability to lead the company forward.
- The new appointments are strategic moves to align the Board with Alnylam's vision of becoming a top-tier biotechnology company, pioneering transformative medicines.
Alnylam's recent Board changes mark a pivotal moment in the company's journey, reflecting a commitment to strategic evolution and sustainable growth in the biopharmaceutical industry.